Aethlon Medical, Inc. Names Charles J. Fisher as Chairman of the Board
November 29, 2017 at 07:45 am EST
Share
Aethlon Medical, Inc. announced the appointment of Charles J. Fisher, Jr., MD as Chairman of its Board of Directors. The Aethlon Board of Directors unanimously nominated Dr. Fisher to be non-Executive Chairman and he will remain an independent director under Nasdaq rules. Dr. Fisher is a physician scientist with a distinguished career in both academia and industry spanning over 30 years. As an experienced executive and entrepreneur, he brings a successful track record of developing operating strategies that take products to markets, drive sales and build profitable companies. Prior to joining industry, Dr. Fisher served as Head of the Section of Critical Care Medicine at The Cleveland Clinic Foundation.
Aethlon Medical, Inc. (Aethlon) is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections suppression, seed the spread of metastasis and inhibit the benefit of cancer therapies. The Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression. Hemopurifier helps to bind and clear multiple different glycosylated viruses, such as human immunodeficiency virus (HIV), hepatitis C virus (HCV), Dengue, West Nile, multiple strains of influenza, Ebola, Chikungunya, smallpox, monkeypox, multiple herpes viruses, a MERS-CoV related pseudovirus, and others. Hemopurifier is used as a device for two independent indications: the treatment of individuals with advanced or metastatic cancer and the treatment of life threating viruses that are not approved therapies.
AETHLON MEDICAL, INC. 
